← All trials
NCT04361032
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 4, 2020
- Primary completion
- Sep 4, 2020
- Completion date
- Oct 4, 2020
- First posted
- Apr 24, 2020
- Last posted
- May 6, 2020
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abderrahmane Mami HospitalLead sponsor
- Abderrahmane Mami HospitalReponsible party - principal investigator
- DatametrixCollaborator
- Eshmoun Clinical Research CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.